5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine

Aim This study compared the 5‐year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model. Research Desig...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2024-02, Vol.26 (2), p.463-472
Hauptverfasser:	Niu, Shu, Alkhuzam, Khalid A., Guan, Dawei, Jiao, Tianze, Shi, Lizheng, Fonseca, Vivian, Laiteerapong, Neda, Ali, Mohammed K., Schatz, Desmond A., Guo, Jingchuan, Shao, Hui
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antidiabetics Blood pressure cardiovascular disease Cardiovascular diseases Clinical trials Diabetes diabetes complications Diabetes Complications - drug therapy Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Hemoglobin Humans Hypoglycemic Agents - adverse effects Insulin Insulin Glargine - adverse effects Microvasculature Prospective Studies semaglutide tirzepatide trial extrapolation type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!